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1. Introduction 
Herbal medicines play an increasingly important role in the perception of physicians and 
patients looking for equally effective, albeit safer approaches to conventional management 
of acute bronchitis. A no antibiotic or delayed antibiotic prescribing strategy to reduce the 
inappropriate prescribing of antibiotics for respiratory tract infections (RTI) has been 
advocated since the late 1990’s (Little, 2005). In the light of inappropriate antibiotic use in 
this indication especially in children and increasing drug resistance rates worldwide, the 
need for an alternative remedy is crucial (Abbas et al., 2010). There is encouraging evidence 
derived from high quality randomised clinical trials (RCTs) that EPs 76301, a herbal drug 
preparation from the roots of Pelargonium sidoides widely used in several countries for the 
treatment of RTIs in children (≥1 year of age) and adults, is effective in patients with acute 
bronchitis. 
2. EPs 7630 – from traditional herbal medicine to modern phytotherapy 
Pelargonium sidoides, a member of the Geraniaceae family, can readily be recognized by its 
dark-red, almost black flowers, the large, heart-shaped leaves and thick rhizomes (Figure 1). 
The plant is native to the coastal regions of South Africa. For centuries, crude root drug of 
initially unknown botanical origin has been traditionally used among Zulus of South Africa 
for the treatment of pulmonary disease and tuberculosis. In the late 19th century, the 
Englishman Charles H. Stevens introduced the crude herbal drug as “Stevens’ cure” in 
Europe after he had been cured from tuberculosis. In the 1920’s, the former missionary and 
physician Dr. A. Sechehaye treated around 800 tuberculosis patients with the drug and 
published his 9-year experience concluding that clear healing effects could be seen 
(Sechehaye, 1937). It was not before the 1970’s, however, that professional search and initial 
chemical and taxonomic investigations undertaken by German researchers revealed that the 
crude herbal drug must have originated from Pelargonium species, i.e. P. sidoides DC and 
the closely related P. reniforme Curt (Bladt & Wagner 2007; Kolodziej 2007; Brendler & van 
Wyk, 2008). The chemical profile of the Pelargonium sidoides root was identified and as 
research progressed, a proprietary extraction technique was developed and perfected to 
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yield the herbal drug preparation EPs 7630 from the roots of Pelargonium sidoides (1:8-10), 
extraction solvent: ethanol 11% (w/w). 
 
    
Fig. 1. Pelargonium sidoides (rhizomes, leaves and flowers)  
3. Phytochemistry and pharmacology 
3.1 Constituents of the Pelargonium sidoides preparation EPs 7630 
Up to now, about three-quarters of the compositional profile of EPs 7630 is known. EPs 7630 
contains primarily phenolic and polyphenolic compounds, proteins, minerals, coumarin 
derivatives (coumarin sulphates and coumarin glycosides) and a number of miscellaneous 
uncommon metabolites (Schötz et al., 2008) (Figure 2). The 7-hydroxycoumarin (including 
umckalin) derivatives differ in chemical structure from the known anticoagulant coumarins 
and are not associated with anticoagulant activity or interaction with warfarin and its 
pharmacokinetics (Koch & Biber, 2007). 
Pharmacological studies have suggested that the mechanism of action of EPs 7630 is multi-
factorial including antibacterial and antiviral potencies and notable immune modulatory 
capabilities as well as cytoprotective effects (Kolodziej et al., 2003; Kolodziej & Kiderlen, 
2007; Thäle et al., 2011; Michaelis et al., 2011). In vitro studies with EPs 7630 demonstrated a 
moderate direct antibacterial activity against various gram-positive and gram-negative 
bacteria (Kolodziej et al., 2003), a strong indirect antibacterial activity like inhibition of 
interaction between group A-streptococci and host epithelia (Conrad et al., 2007b), 
improved phagocytosis, improved oxidative burst and intracellular killing by human 
peripheral blood phagocytes (Conrad et al., 2007a) and antiviral properties, e.g. interference 
on replication of a panel of seasonal respiratory viruses such as H1N1 (Michaelis et al., 
2011). Furthermore, in-vitro studies have found that EPs 7630 exerts a cytoprotective effect 
against virus-induced cell destruction and also increases release of antimicrobial peptides 
(also known as defensins) from neutrophilic granulocytes (Koch & Wohn, 2007; Kolodziej & 
Schulz, 2003). The immune-modulatory activities are mainly mediated by the release of 
tumour-necrosis factor (TNF-ǂ) and nitric oxide (Kolodziej & Kiderlen, 2007; Thäle et al., 
2011), stimulation of interferon-ǃ (Kolodziej et al., 2003) and an increase in natural killer cell 
activity (Koch et al., 2002). In cell cultures, EPs 7630 has been found to stimulate the ciliary 
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beat frequency (Neugebauer et al., 2005), which may support a secromotoric effect during 
acute respiratory tract infections. Finally, EPs 7630 inhibits the lipopolysaccharide-induced 
sickness behaviour in mice in vivo (Nöldner & Schötz, 2007). 
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Fig. 2. Constituents of Pelargonium sidoides root preparation EPs 7630 
4. Clinical research in acute bronchitis 
The efficacy and safety of EPs 7630 in the treatment of acute respiratory tract infections has 
been studied in over 3,500 patients of placebo-controlled double-blind clinical studies and in 
over 5,500 patients of open-label and non-interventional (post-marketing surveillance) 
studies. Out of the total of over 9,000 patients, about 4,000 were children and adolescents. 
EPs 7630 has been shown to be effective and safe in the treatment of acute upper respiratory 
tract infections, including bronchitis, tonsillopharyngitis, sinusitis, and common cold 
(Brown, 2009). A meta-analysis of randomised clinical trials with EPs 7630 in acute 
respiratory tract infections published by the Cochrane Collaboration (Timmer et al., 2008) 
showed that EPs 7630 was effective in alleviating the disease-specific symptoms of acute 
bronchitis, particularly coughing and sputum production. In acute sinusitis and common 
cold, EPs 7630 also was effective in resolving all symptoms including headaches and nasal 
discharge. Another meta-analysis reviewed 6 randomised, controlled clinical studies 
investigating EPs 7630 in acute bronchitis in both adults and children (Agbabiaka et al., 
2008). While one double-dummy study compared EPs 7630 against N-acetylcysteine, the 
other 5 were placebo-controlled trials. Treatment duration was 7 days. The primary outcome 
variable was the change in the total Bronchitis Severity Score (BSS) from baseline to the end 
of the study. The BSS consists of 5 items which are the most important features associated 
with acute bronchitis and considered to be of clinical relevance (Franks & Gleiner, 1984; 
Knutson & Braun, 2002; Macfarlane et al., 2002; Williamson, 1984), i.e. coughing, sputum 
production, pulmonary rales at auscultation, chest pain while coughing, and dyspnoea, each 
symptom being scored by the investigator using a 5-point rating scale ranging from 0 (not 
present) to 4 (very severe). The meta-analysis showed that EPs 7630 compared to placebo 
significantly decreased the total BSS within 7 days of treatment (calculated weighted mean 
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differences 2.80 points, 95% confidence interval 2.44-3.15) with improvement in individual 
components of the BSS.  
Up to now, more than 2,500 patients (including about one third adolescents and children, 
aged ≥1 year) have been included into randomised placebo-controlled clinical trials in order 
to investigate the efficacy and safety of EPs 7630 in acute bronchitis. The latest high quality 
studies are outlined in the following.  
4.1 Major randomised clinical trials in adults 
All of the three recently published major clinical studies in adults suffering from acute 
bronchitis were randomised, double-blind, placebo-controlled multicentre trials 
investigating the efficacy and tolerability of EPs 7630 in patients (≥ 18 years) (Chuchalin et 
al., 2005; Matthys & Heger 2007; Matthys et al. 2010a,b). Major inclusion criteria in all three 
trials were a total BSS of ≥ 5 points and acute bronchitis symptoms having started ≤ 48 hours 
prior to study entry. The individual treatment period lasted 7 days including three visits 
(day 0, day 3 to 5, and day 7). In case of a fever (≥ 39° C), paracetamol tablets (500 mg) were 
allowed (maximum 3 tablets per day). Primary endpoint in all three studies was the change 
in the total BSS from baseline to day 7. Secondary outcome measures were: Change of 
individual symptoms of the BSS; change in general symptoms (hoarseness, headache, limb 
pain and fatigue/exhaustion) with the following definition of change: complete remission 
(symptoms present on day 0 had completely resolved on day 7), improvement (any decrease 
in symptom intensity from day 0 to day 7, except remission), no change (no change in 
symptom intensity from day 0 to day 7), deterioration (any increase in symptom intensity 
from day 0 to day 7); treatment outcome assessed by both the patient and the investigator 
using the Integrative Medicine Outcomes Scale (IMOS) which is widely used in 
conventional research as well as in complementary and alternative medicine research and 
describes the general health status of the patient (Steinsbekk et al., 1999). It consists of 5 
items: complete recovery, major improvement, slight to moderate improvement, no change, 
and deterioration; patient’s satisfaction with treatment using the Integrative Medicine 
Patient Satisfaction Scales (IMPSS) which describes the patient’s satisfaction with the 
treatment and consists of 5 items: very satisfied, satisfied, neutral, dissatisfied, very 
dissatisfied (Steinsbekk et al., 1999); onset of treatment effect; duration of activity limitation 
and duration of inability to work; intake of paracetamol and the general health status using 
health-related quality of life questionnaires (EQ-5D and EQ VAS (EQ-5D, 2011), SF-12 
Health Survey (Ware et al., 1996)). In addition, adverse events (AEs), laboratory safety 
parameters, and vital parameters were recorded. 
In the trial reported by Chuchalin and colleagues (2005), 124 adults (≥ 18 years) suffering 
from acute bronchitis received either 3x30 drops/d EPs 7630 solution (n=64) or matched 
placebo (n=60) for 7 days. At baseline, the mean total BSS was similar in both treatment 
groups (Figure 3). According to the intention-to-treat analysis at day 7, the total BSS 
(mean±standard deviation) decreased by 7.2±3.1 points in the EPs 7630 group compared 
with 4.9±2.7 points in the placebo group (p<0.0001). The treatment effect was already 
significantly larger at the first follow-up contact (day 3-5) with a total BSS of 4.4±2.2 points 
in the EPs 7630 group and 6.2±2.5 points in the placebo group (p<0.0001). On day 7, the rate 
of complete remission from individual symptoms of the BSS was considerably higher in the 
EPs 7630 group. Pulmonary rales at auscultation, for instance, disappeared in 55/60 patients 
(91.7%) in the EPs 7630 group compared with 29/59 patients (49.2%) in the placebo group 
(p<0.0001), chest pain while coughing resolved in 55/58 patients (94.8%) of the EPs 7630 
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group and 29/52 patients (55.8%) of the placebo group, respectively (p<0.0001), and for 
coughing, the rate of complete remission was also significantly higher in the EPs 7630 group 
compared to the placebo group (31.3% versus 5.0%; p<0.0001). Furthermore, all five general 
symptoms showed higher recovery and improvement rates in the EPs 7630 group compared 
with placebo. According to the IMOS assessment carried out by the investigator on day 7, 
54/64 patients (84.4%) in the EPs 7630 group were judged as completely recovered or 
having major improvement compared with 18/60 patients (30.0%) in the placebo group. The 
IMOS assessment by the patient showed similar results. Correspondingly, 51/64 patients 
(79.7%) in the EPs 7630 group and 26/60 patients (43.3%) in the placebo group were satisfied 
with their treatment according to the IMPSS (p<0.0001). The results also indicated a better 
health-related quality of life according to EQ-5D, EQ VAS and SF-12 Health Survey for those 
patients treated with EPs 7630 compared to placebo patients. For instance, the EQ VAS 
increased by 34 units in the EPs 7630 group and by 24 units in the placebo group (p=0.001). 
From the results of this study the authors concluded that EPs 7630 was superior in efficacy 
compared with placebo in the treatment of adults with acute bronchitis and may therefore 
offer an effective alternative treatment unless antibiotics are clearly indicated.  
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Fig. 3. Time course of the total Bronchitis Severity Score (BSS) during treatment (n=124, ITT 
analysis) 
In the second study, published by Matthys & Heger (2007), 217 patients (≥ 18 years) with 
acute bronchitis were randomised to the same dose regimen (either 3x30 drops/d EPs 7630 
solution (n=108) or matched placebo (n=109) for a period of 7 days). At baseline, the mean 
total BSS was 8.9±1.6 points in the active treatment group and 8.4±1.8 points in the placebo 
group. Between baseline and day 7, the mean total BSS decreased by 7.6±2.2 points in the 
EPs 7630 group and 5.3±3.2 points in the placebo group (p<0.0001) (Figure 4). The 
percentage of patients reporting complete remission of each of the five individual symptoms 
in the BSS on day 7 was higher in the EPs 7630 group (Figure 5). The difference between the 
two study groups was most pronounced for the symptoms coughing and rales at 
auscultation followed by sputum, dyspnoea and chest pain while coughing. For coughing 
56/108 (51.9%) of EPs 7630 patients versus 13/109 (11.9%) of placebo patients reported a 
complete remission and none of the patients under EPs 7630 treatment had reported a 
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deterioration compared to 5/109 (4.6%) patients under placebo. For pulmonary rales at 
auscultation the complete remission rate was 82/93 (88.2%) of EPs 7630 patients compared 
to 44/88 (50.5%) of placebo patients. Similar results were noted for the general symptoms of 
acute bronchitis monitored. According to the IMOS assessment by the investigator on day 7, 
complete recovery or major improvement was reported in 89.8% of EPs 7630 patients 
compared with 65.1% of placebo patients. The IMOS as assessed by the patient showed 
similar results. According to the IMPSS rating, 91/108 (84.3%) of patients in the EPs 7630 
group were very satisfied or satisfied with treatment in comparison with 52/109 (47.7%) 
patients in the placebo group. The authors concluded that EPs 7630 solution was a well 
tolerated and effective treatment for acute bronchitis in adults outside the strict indication 
for an antibiotic therapy.  
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Fig. 4. Time course of the total Bronchitis Severity Score (BSS) during treatment (n=214, ITT 
analysis) 
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Fig. 5. Patients with complete remission of the individual bronchitis symptoms on day 7 
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In a dose-finding study using an adaptive group-sequential design (Matthys et al., 2010b), 
406 patients (≥ 18 years) were randomly assigned to one of four parallel treatment groups 
(EPs 7630 film-coated tablets: 3x10mg (30mg group, 102 patients), 3x20mg (60mg group, 101 
patients), or 3x30mg (90mg group, 100 patients) or 3x placebo film-coated tablets (102 
patients) daily for a treatment period of 7 days. 405 patients could be evaluated for the full 
analysis set. At baseline, the mean total BSS was similar in the four treatment groups (Figure 
6). Between day 0 and day 7, the mean total BSS decreased by 2.7±2.3 points for placebo, 
4.3±1.9 points for the 30mg group, 6.1±2.1 points for the 60mg group and 6.3±2.0 points for 
the 90mg group, respectively. The tests of the global hypotheses including the pair-wise 
comparisons of each active treatment group to placebo applying ANCOVA analysis, 
revealed statistically significant differences for all EPs 7630 groups (p<0.0001, in each case, 
one-sided). A considerable difference in the total BSS for the EPs 7630 groups compared to 
placebo was already observed on day 3-5 and further increased to day 7 in a dose-
dependent manner. 
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Fig. 6. Time course of the total Bronchitis Severity Score (BSS) during treatment (n=405, ITT 
analysis) 
The mean decrease in the five individual BSS items from day 0 to day 7 was markedly more 
pronounced in the active treatment groups compared to placebo. The reduction in the 
intensity of each symptom increased in a statistically significant way with the EPs 7630 dose 
(p<0.0001, in each case, Bartholomew-test). Pair-wise comparison with placebo showed that 
the effect of EPs 7630 (complete remission and improvement) on coughing and pulmonary 
rales at auscultation from day 0 to day 7 was statistically significant (p<0.0001, in each case, 
two-sided t-test). For sputum, chest pain while coughing and dyspnoea, statistically 
significant differences were observed between placebo and the 60mg and 90mg groups, 
respectively (p<0.0001, in each case, two-sided t-test). A statistically significant dose-
dependent effect on the change in the general symptoms hoarseness (p=0.0006), headache 
(p=0.0001), limb pain (p=0.032) and fatigue/exhaustion (p=0.0001) from day 0 to day 7 
could also be shown for EPs 7630 (Bartholomew-tests). The onset of treatment effect 
occurred significantly earlier in each EPs 7630 treatment group compared with placebo 
(p<0.0001, in each case, two-sided Mantel-Haenszel χ2-test). In the placebo group, 42.2% of 
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patients reported no treatment effect at all. The results of the investigator’s assessment on 
day 7 according to treatment outcome (IMOS) showed a markedly higher rate of complete 
recovery and improvement in the active treatment groups compared with placebo (p<0.0001 
for all pair-wise comparisons with placebo, two-sided Mantel-Haenszel χ2-test) (Figure 7). 
This applied to the patients’ IMOS assessment as well. Evaluation of patients’ satisfaction 
with treatment (IMPSS) on day 7 showed comparable results (p<0.0001 for all pair-wise 
comparisons of the individual categories, two-sided Mantel-Haenszel χ2-test). The 
percentage of patients able to work at day 7 was significantly higher in all three EPs 7630 
treatment groups compared to placebo (p<0.0001) (Figure 8). The median duration of 
inability to work was 8 days for placebo and 6 days for EPs 7630 treated patients, i.e. a 
reduction by 2 days could be seen in all active treatment groups (p<0.0001, in each case, 
two-sided U-test).  
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Fig. 7. Treatment outcome (IMOS): Assessment by the investigator on day 7 (p<0.0001 for all 
pair-wise comparisons with placebo) 
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Fig. 8. Percentage of patients able to work on day 0 and day 7, respectively (p<0.0001 
compared to placebo) 
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Across all five items of the EQ-5D questionnaire (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression), the number of patients with remission or 
improvement was significantly higher in the EPs 7630 treatment groups when compared 
with the placebo group (p<0.05 for all pair-wise comparisons, two-sided U-test) except for 
the symptom anxiety/depression in the 30mg and 60mg group for which the advantage was 
not significant (Matthys et al., 2010b). The assessment of the health status on a visual scale 
according to the EQ VAS on day 7 showed a significant higher improvement rate in the 
active treatment groups (34.5±19.0; 41.4±18.9 and 38.7±17.3 in the 30mg, 60mg and 90mg 
group, respectively) compared to placebo (20.0±18.9) (p<0.0001, two-sided Wilcoxon test) 
(Figure 9). The assessment of physical and mental health status according to the SF-12 
revealed a much more pronounced improvement in the active treatment groups versus 
placebo for the physical component score (p<0.0001 for all pair-wise comparisons with 
placebo, two-sided t-test). It was concluded that a daily dose of 60mg EPs 7630 could 
represent the optimal dose for EPs 7630 tablets with respect to the benefit-risk-ratio.  
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Fig. 9. Time course of health related quality of life: EQ VAS (0=worst imaginable health 
state, 100=best imaginable health state; n=405, ITT analysis)  
4.2 Major randomised clinical trials in children and adolescents  
The two recently published major clinical studies in children and adolescents (Kamin et al., 
2010a,b) are randomised, double-blind, placebo-controlled multicentre trials, which 
evaluated the efficacy and tolerability of EPs 7630 in children and adolescents (1-18 years) 
with acute bronchitis. Major inclusion criteria were a total BSS of ≥ 5 points and acute 
bronchitis symptoms having started ≤ 48 hours prior to study entry. The individual period 
of double-blind treatment lasted 7 days including three visits (day 0, day 3 to 5, and day 7). 
The primary outcome parameter was the change in the total BSS from baseline to day 7. 
Secondary outcome measures were the change in individual symptoms of the BSS; change 
of other general symptoms, e.g. headache, absence of appetite, and vomiting; treatment 
outcome assessed by both the patient or the legal representatives of the patients (patient’s 
assessment) and the investigator using the Integrative Medicine Outcomes Scale (IMOS); 
patient’s satisfaction with treatment using the Integrative Medicine Patient Satisfaction 
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Scales (IMPSS); onset of treatment effect; ability to attend kindergarten, school or work, and 
quality of life by means of the FGK questionnaire (i.e. questionnaire for health state of 
children, which consists of 6 questions). In addition, adverse events (AEs), laboratory safety 
parameters, and vital parameters were documented. 
In the first study (Kamin et al. 2010a), 200 children (EPs 7630: 103; placebo: 97) aged 1 to 18 
years and suffering from acute bronchitis were randomly assigned and stratified to one of 
two parallel treatment groups according to age: Patients 1 to 6 years: 3x10 drops, patients >6 
to 12 years: 3x20 drops, patients > 12-18 years: 3x30 drops EPs 7630 per day or matched 
placebo for 7 consecutive days. For the statistical analysis, the total BSS comprising the 
objectively assessable three BSS items coughing, pulmonary rales at auscultation and 
dyspnoea was considered. At baseline, the mean total BSS was similar in both treatment 
groups (Figure 10). From baseline to day 7, the mean total BSS improved by 3.4±1.8 points in 
the EPs 7630 group compared with 1.2±1.8 points in the placebo group (p<0.0001, 
ANCOVA).  
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Fig. 10. Time course of the total Bronchitis Severity Score (BSS) during treatment (n=200, ITT 
analysis) 
The decrease in the mean total BSS from day 0 to day 7 was more pronounced in the EPs 
7630 group compared to placebo with significant differences in the individual symptoms 
coughing and pulmonary rales at auscultation in favour of the EPs 7630 group (both with 
p-values <0.0001, two-sided t-test). The assessment of general symptoms showed 
pronounced improvement in the active treatment group and was significant for the items 
absence of appetite and headache (p<0.0001 and p=0.0003, respectively, two-sided t-test). 
The onset of treatment effect occurred significantly earlier in the EPs 7630 group as 
compared to placebo (p<0.0001, two-sided Mantel-Haenszel χ2-test). The results of the 
evaluation of treatment outcome (IMOS) by the investigator at day 7 showed a 
significantly better IMOS outcome for patients treated with EPs 7630 than placebo 
(p<0.0001, two-sided Mantel-Haenszel χ2-test). The rates of patients showing complete 
recovery or major improvement were 77.7% for EPs 7630 and 19.6% for placebo (Figure 
11). Patients’ IMOS assessments showed a very strong agreement with the assessments  
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Fig. 11. Treatment outcome (IMOS), assessment by the physician on day 7 
made by the investigators. In the EPs 7630 group, the number of patients keeping bed rest 
dropped from 42.7% (44/103) at baseline to 1.9% (2/103) patients on day 7 compared with a 
decrease from 42.3% (41/97) to 18.6% (18/97) for patients in the placebo group. 
Correspondingly, the number of patients able to attend kindergarten, school or work on day 7 
increased more markedly in the EPs 7630 group than in the placebo group (50/103 patients 
(48.5%) of the EPs 7630 group and 12/97 patients (12.4%) of the placebo group) (Figure 12).  
 
Placebo (n=97)
EPs 7630 (n=103)
0
10
20
30
40
50
60
Day 0 Day 7
%
 P
a
ti
e
n
ts
 
Fig. 12. Number of patients able to attend kindergarten, school or work on day 0 and on  
day 7, respectively 
The satisfaction of patients with treatment as assessed by the IMPSS on day 7 was also 
significantly positive in the EPs 7630 group (p<0.0001, two-sided Mantel-Haenszel χ2-test) 
(Figure 13). Health status and quality of life as assessed by the FGK questionnaire showed 
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significantly better results for the EPs 7630 group compared with placebo. For each FGK 
statement, namely “everything is too much for me” (1.0±1.2 vs. 0.3±1.3 points, p<0.0001), “I am 
feeling ill” (1.8±0.8 vs. 1.0±1.1 points, p<0.0001), “I am scared” (0.8±0.7 vs. 0.3±0.9 points, 
p=0.0002), “I have trouble playing or learning” (1.7±0.9 vs. 0.8±1.1 points, p<0.0001), “I sleep 
bad” (1.6±0.9 vs. 0.9±1.2 points, p<0.0001) and “I have problems getting into conversation with 
others”(1.2±1.0 vs. 0.6±1.0 points, p=0.0001), the two-sided t-test showed a significant 
advantage for the EPs 7630 group compared with placebo. The authors concluded that EPs 
7630 was shown to be efficacious and safe in the treatment of acute bronchitis in children and 
adolescents outside the strict indication for antibiotics and that patients treated with EPs 7630 
perceived a more favourable course of the disease and a good tolerability as compared with 
placebo.  
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Fig. 13. Patients’ satisfaction with treatment (IMPSS) on day 7  
In the second study (Kamin et al., 2010b), which was a placebo-controlled clinical dose-
finding trial, 400 children and adolescents (6-18 years) with acute bronchitis were 
randomly assigned to one of four parallel treatment groups and received EPs 7630 as film-
coated tablets at the following dose levels: 3x10mg (= 30mg group, 100 patients), 3x20mg 
(= 60mg group, 99 patients) or 3x30mg/d (= 90mg group, 99 patients) or matched placebo 
(101 patients) for 7 consecutive days. One patient in the 30mg group was an early drop 
out, thus the analysis included 399 patients. The evaluation of the total BSS comprised all 
five symptoms. At baseline, the mean total BSS was similar in the four treatment groups 
(Figure 14). The decrease in the mean total BSS between day 0 and day 7 was more 
pronounced in the active treatment groups as compared to the placebo group (placebo: 
3.3±2.6, EPs 7630 (30mg): 3.6±2.4, EPs 7630 (60mg): 4.4±2.4, EPs 7630 (90mg): 5.0±1.9). The 
pair-wise comparisons of each active treatment group to placebo using the ANCOVA 
model revealed statistically significant differences in the decrease in the total BSS for the 
EPs 7630 60mg and 90mg group (p=0.0004 and p<0.0001, respectively, two-sided 
ANCOVA p-values).  
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Fig. 14. Time course of the total Bronchitis Severity Score (BSS) during treatment (n=399, ITT 
analysis) 
The mean decrease in the individual BSS items coughing, sputum, pulmonary rales at 
auscultation, chest pain while coughing and dyspnoea from day 0 to day 7 was markedly 
more pronounced in the EPs 7630 (60mg) and EPs 7630 (90mg) groups than in the placebo 
group. The active treatment groups showed a significant dose-dependent advantage 
compared to placebo for the symptoms coughing (p<0.0001), sputum (p=0.0016) and 
pulmonary rales at auscultation (p<0.0001, two-sided t-test, each). A statistically 
significant dose-depending effect of EPs 7630 on the general symptoms absence of 
appetite (p=0.0234), headache (p=0.0112), vomiting (p=0.0142) from day 0 to day 7 could 
also be shown (Bartholomew test). Patients in both the EPs 7630 (60mg) and EPs 7630 
(90mg) groups reported an earlier onset of treatment effect (p=0.0060 and p<0.0001, 
respectively, two-sided Mantel-Haenszel χ2-test). Evaluation of the treatment outcome by 
the investigator using the IMOS showed a significantly better treatment outcome for the 
EPs 7630 90mg and 60mg groups than for placebo (p=0.0005 and p<0.0001, respectively, 
two-sided Mantel-Haenszel χ2-test) (Figure 15). The IMOS results as assessed by the 
patient were comparable. The satisfaction of patients evaluated using IMPSS was better in 
the EPs 7630 groups compared with placebo. Patients were more often satisfied or very 
satisfied in the active treatment groups (57.0% for EPs 7630 (30mg), 66.7% for EPs 7630 
(60mg), 81.8% for EPs 7630 (90mg)) than in the placebo group (45.5%). Between day 0 and 
day 7, the number of patients able to attend kindergarten, school or work improved 
markedly in all groups, especially in the EPs 7630 (60mg) and EPs 7630 (90mg) groups. At 
day 0, only 1 patient (1%) was able to attend kindergarten, school or work in the placebo 
and 60mg groups, respectively. At day 7, 33.7% (placebo), 35.0% (EPs 7630 (30mg) group), 
44.4% (EPs 7630 (60mg) group) and 53.5% (EPs 7630 (90mg) group) had regained this 
ability (Figure 16). 
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Fig. 15. Treatment outcome (IMOS), assessment by the physician on day 7 
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Fig. 16. Number of patients able to attend kindergarten, school or work on day 0 and on day 7, 
respectively 
In all groups, an improvement in health status as assessed by the FGK questionnaire could 
be seen between day 0 and day 7. This improvement was more pronounced in the EPs 7630 
(60mg) and EPs 7630 (90mg) groups as compared with placebo. Based upon these findings 
the authors concluded that a daily dose of 60mg EPs 7630 (20mg three times per day) 
represents the optimal dose for the treatment of acute bronchitis in children and adolescents 
with respect to the benefit-risk-ratio.  
5. Safety and tolerability  
The safety profile of EPs 7630 has been systematically reviewed based upon 25 clinical trials 
and post-marketing surveillance studies with a total of more than 9,000 patients - including 
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paediatric safety with about 4,000 children and adolescents - suffering from acute or 
exacerbation of chronic respiratory tract infections such as bronchitis, tonsillopharyngitis or 
sinusitis (Matthys & Köhler, 2010). EPs 7630 was well tolerated and no serious adverse drug 
reactions were reported in this large patient population. Comparing EPs 7630 and placebo, 
adverse events were similar with regard to quality and quantity throughout almost all organ 
systems and symptoms, the only difference being a slightly higher incidence of 
gastrointestinal disorders (epigastric pain, nausea, diarrhoea) and of hypersensitivity 
reactions (mostly skin reactions), as well as gingival bleeding and epistaxis associated with 
EPs 7630 compared to placebo.  
EPs 7630 is contraindicated during pregnancy and lactation due to a lack of safety data in 
this population, as well as in patients with hypersensitivity to the active substance or to any 
of the excipients. Up to now, there are no known contraindications to concomitant use of 
EPs 7630 with other medicinal products. 
6. Conclusion 
The results of the recently published high quality randomised clinical trials and 
independent meta-analyses show that EPs 7630 is an efficacious, safe, and well-tolerated 
herbal medicine in the management of acute respiratory tract infections (bronchitis, 
sinusitis, and tonsillopharyngitis) in children, adolescents and adults. The studies 
demonstrate both a statistically significant and clinically relevant superiority of EPs 7630 
with respect to efficacy and a more favourable course of the disease and a faster recovery 
of patients compared to placebo. EPs 7630 was well tolerated and can therefore be 
considered to be a safe therapeutic alternative in the first-line treatment of acute 
bronchitis and as a reasonable choice for all patients outside the strict indication for 
antibiotics. 
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